Ryan Dittamore
Overview
Explore the profile of Ryan Dittamore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
1866
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Conteduca V, Ku S, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al.
NPJ Precis Oncol
. 2021 Sep;
5(1):84.
PMID: 34518634
No abstract available.
2.
Conteduca V, Ku S, Fernandez L, Dago-Rodriquez A, Lee J, Jendrisak A, et al.
NPJ Precis Oncol
. 2021 Aug;
5(1):76.
PMID: 34385567
Neuroendocrine prostate cancer is an aggressive variant of prostate cancer that may arise de novo or develop from pre-existing prostate adenocarcinoma as a mechanism of treatment resistance. The combined loss...
3.
Chalfin H, Pramparo T, Mortazavi A, Niglio S, Schonhoft J, Jendrisak A, et al.
Clin Cancer Res
. 2020 Dec;
27(5):1391-1398.
PMID: 33262136
Purpose: Circulating tumor cells (CTC) are under investigation as a minimally invasive liquid biopsy that may improve risk stratification and treatment selection. CTCs uniquely allow for digital pathology of individual...
4.
Circulating Tumor Cells as a Predictor of Treatment Response in Clinically Localized Prostate Cancer
Salami S, Singhal U, Spratt D, Palapattu G, Hollenbeck B, Schonhoft J, et al.
JCO Precis Oncol
. 2020 Aug;
3.
PMID: 32832835
Purpose: Using nonenrichment-based, potentially more sensitive Epic Sciences circulating tumor cell (CTC) platform, we sought to detect and characterize CTCs in untreated, high-risk localized prostate cancer and to evaluate their...
5.
Schonhoft J, Zhao J, Jendrisak A, Carbone E, Barnett E, Hullings M, et al.
Cancer Res
. 2020 Aug;
80(22):4892-4903.
PMID: 32816908
Chromosomal instability (CIN) increases a tumor cell's ability to acquire chromosomal alterations, a mechanism by which tumor cells evolve, adapt, and resist therapeutics. We sought to develop a biomarker of...
6.
Necchi A, Raggi D, Giannatempo P, Marandino L, Fare E, Gallina A, et al.
Eur Urol Oncol
. 2020 May;
4(6):1001-1005.
PMID: 32417369
In the PURE-01 study, patients with muscle-invasive bladder cancer (MIBC) who achieved a pathological complete response (CR; ypT0N0) had tumor features suggesting that pre-existing immunity may promote response. We focused...
7.
Malihi P, Graf R, Rodriguez A, Ramesh N, Lee J, Sutton R, et al.
Clin Cancer Res
. 2020 Apr;
26(15):4143-4153.
PMID: 32341031
Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) , and ....
8.
Necchi A, Raggi D, Gallina A, Ross J, Fare E, Giannatempo P, et al.
Eur Urol
. 2020 Mar;
77(6):701-710.
PMID: 32165065
Background: The PURE-01 study (NCT02736266) evaluated the use of pembrolizumab before radical cystectomy (RC) in muscle-invasive bladder cancer (MIBC). Objective: To evaluate the ability of molecular signatures to predict the...
9.
Conteduca V, Ku S, Puca L, Slade M, Fernandez L, Hess J, et al.
Mol Cancer Ther
. 2020 Mar;
19(5):1157-1164.
PMID: 32127465
Expression of the DNA/RNA helicase schlafen family member 11 (SLFN11) has been identified as a sensitizer of tumor cells to DNA-damaging agents including platinum chemotherapy. We assessed the impact of...
10.
Febbo P, Martin A, Scher H, Barrett J, Beaver J, Beresford P, et al.
Clin Pharmacol Ther
. 2020 Feb;
107(4):730-734.
PMID: 32017048
No abstract available.